Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.50 |
| ▸ | TEK | Q02763 | 2/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | EIF2AK3 | Q9NZJ5 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090548 | 0.91 | NTRK1 (0.49) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4086297 | 0.91 | EGFR (0.61) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4090065 | 0.91 | NTRK1 (0.49) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4080442 | 0.90 | NTRK1 (0.58) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4079994 | 0.90 | NTRK1 (0.50) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL1940512 | 0.90 | EGFR (0.62) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4089434 | 0.86 | NTRK1 (0.48) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4080424 | 0.86 | NTRK1 (0.48) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4086285 | 0.85 | NTRK1 (0.49) | EGFRERBB2ERBB3TEKERBB4 | |
| SCHEMBL4076555 | 0.84 | NTRK1 (0.50) | EGFRERBB2ERBB3TEKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595325-B2 | Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatment | PFIZER INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1773836-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | Pfizer Products Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | PFIZER INC | 2006-02-16 | — | — | US | disclosed |
| WO-2005116035-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL IN CANCER TREATMENT | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035912-A1 | Pyrrolopyrimidine derivatives useful in cancer treatment | TP53, DPYD, CCNT1 | EGFR 864/4885ERBB2 1637/4885ERBB3 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.